9 reports of this reaction
1.5% of all ARFORMOTEROL TARTRATE reports
#14 most reported adverse reaction
OXYGEN SATURATION DECREASED is the #14 most commonly reported adverse reaction for ARFORMOTEROL TARTRATE, manufactured by Alembic Pharmaceuticals Inc.. There are 9 FDA adverse event reports linking ARFORMOTEROL TARTRATE to OXYGEN SATURATION DECREASED. This represents approximately 1.5% of all 613 adverse event reports for this drug.
Patients taking ARFORMOTEROL TARTRATE who experience oxygen saturation decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OXYGEN SATURATION DECREASED is a less commonly reported adverse event for ARFORMOTEROL TARTRATE, but still significant enough to appear in the safety profile.
In addition to oxygen saturation decreased, the following adverse reactions have been reported for ARFORMOTEROL TARTRATE:
The following drugs have also been linked to oxygen saturation decreased in FDA adverse event reports:
OXYGEN SATURATION DECREASED has been reported as an adverse event in 9 FDA reports for ARFORMOTEROL TARTRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OXYGEN SATURATION DECREASED accounts for approximately 1.5% of all adverse event reports for ARFORMOTEROL TARTRATE, making it a notable side effect.
If you experience oxygen saturation decreased while taking ARFORMOTEROL TARTRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.